Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Motif Bio Meeting With US FDA Confirms Need For Another iclaprim Trial

Thu, 10th Oct 2019 11:52

(Alliance News) - Motif Bio PLC on Thursday said official minutes of its US regulator meeting confirm a phase three trial of iclaprim, plus data on possible liver injury side effects, are necessary to allow submission of a new drug application.

Shares in Motif were down 7.6% at 0.62 pence in London shortly before midday.

Motif got a complete response letter from the US Food & Drug Administration for iclaprim in February, meaning the FDA had completed its review and opted not to approve the drug application in its current form.

The minutes are from a Tube B meeting with the regulator, which took place September 19. These confirmed the need for a single phase three trial, provided it is well designed and well controlled, which shows the safety and efficacy of the drug in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. The FDA would also require "data on potential mechanisms of hepatic injury" or injury relating to the liver.

Motif said: "Its would take several years to enrol and complete a HABP/VABP phase three trial and the cost is expected to be tens of millions of dollars."

As such, Motif is confident in its belief "the most efficient way" of generating value from iclaprim is if another partner completes the trial.

Chief Executive Graham Lumsden said: "We now have confirmation of what will be required to progress iclaprim towards a potential approval. The company is working hard to find a partner or other entity to complete the HABP/VABP phase three trial, commercialise iclaprim and ensure the best outcome for shareholders in Motif Bio."

On Wednesday last week, Motif said it planned to raise GBP600,000 through a share placing in order to complete a restructure. This restructure will see Motif turn into a cash shell, winding down operations and selling assets, including iclaprim.

The restructure relieves Motif from its liability and guarantee on an approximately USD6.7 million loan from Hercules Capital Inc, with Hercules taking a perfected security interest in all Motif's intellectual property plus a warrant for 20% of Motif's shares.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
14 Jun 2021 20:33

TRADING UPDATES: Motif Bio takeover called off; Yamana buys at Wasamac

TRADING UPDATES: Motif Bio takeover called off; Yamana buys at Wasamac

Read more
26 May 2021 21:28

IN BRIEF: Motif Bio expects market capitalisation of GBP16.2 million

IN BRIEF: Motif Bio expects market capitalisation of GBP16.2 million

Read more
26 May 2021 18:18

TRADING UPDATES: AVI Global sees strong results; Finsbury Food rebound

TRADING UPDATES: AVI Global sees strong results; Finsbury Food rebound

Read more
10 May 2021 15:52

IN BRIEF: Motif Bio 2020 loss narrows due to impairment in prior year

IN BRIEF: Motif Bio 2020 loss narrows due to impairment in prior year

Read more
29 Mar 2021 14:25

IN BRIEF: Motif Bio progresses reverse takeover, expects AIM return

IN BRIEF: Motif Bio progresses reverse takeover, expects AIM return

Read more
26 Feb 2021 20:20

LONDON TRADING UPDATES: Motif Bio Says Orange Avenue Buys Subsidiary

LONDON TRADING UPDATES: Motif Bio Says Orange Avenue Buys Subsidiary

Read more
27 Jan 2021 14:37

IN BRIEF: Motif Bio Making Progress On UK Drug Development Firm Buy

IN BRIEF: Motif Bio Making Progress On UK Drug Development Firm Buy

Read more
5 Jan 2021 15:04

IN BRIEF: Motif Bio Advancing Process To Complete Reverse Takeover

IN BRIEF: Motif Bio Advancing Process To Complete Reverse Takeover

Read more
12 Oct 2020 11:50

Cash Shell Motif Bio Swings To Interim Loss On Derivative Liabilities

Cash Shell Motif Bio Swings To Interim Loss On Derivative Liabilities

Read more
23 Sep 2020 16:13

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
1 Sep 2020 14:08

IN BRIEF: Motif Bio Annual Pretax Loss Narrows Amid Takeover Hopes

IN BRIEF: Motif Bio Annual Pretax Loss Narrows Amid Takeover Hopes

Read more
29 Jul 2020 15:39

IN BRIEF: Motif Bio Shares Suspended; Still Hopes For Reverse Takeover

IN BRIEF: Motif Bio Shares Suspended; Still Hopes For Reverse Takeover

Read more
29 Jul 2020 09:59

Motif Bio shares suspended from trading

(Sharecast News) - Pharmaceutical company Motif Bio saw its shares suspended from trading on Wednesday in order to satisfy AIM rules.

Read more
23 Jun 2020 08:48

CORRECT: Motif Bio Delays 2019 Results As Faces AIM Takeover Deadline

CORRECT: Motif Bio Delays 2019 Results As Faces AIM Takeover Deadline

Read more
22 Jun 2020 14:14

IN BRIEF: Motif Bio Delays 2019 Results As Faces AIM Takeover Deadline

IN BRIEF: Motif Bio Delays 2019 Results As Faces AIM Takeover Deadline

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.